Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?

Obese patients who often present metabolic dysfunction-associated fatty liver disease (MAFLD) are at risk of severe presentation of coronavirus disease 2019 (COVID-19). These patients are more likely to be hospitalized and receive antiviral agents and other drugs required to treat acute respiratory...

Full description

Saved in:
Bibliographic Details
Published in:Biochimie
Main Authors: Ferron, Pierre-Jean, Gicquel, Thomas, Mégarbane, Bruno, Clément, Bruno, Fromenty, Bernard
Format: Artigo
Language:Inglês
Published: Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7468536/
https://ncbi.nlm.nih.gov/pubmed/32891697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biochi.2020.08.018
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items